Halozyme Therapeutics vs Moderna
HALO and MRNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HALO and MRNA compare
Moderna is the larger company, worth 6.0 times as much as Halozyme Therapeutics ($88.5B against $14.9B).
Halozyme Therapeutics grew revenue faster over the last twelve months (41.2% versus −27.6% for Moderna).
Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −141% at Moderna.
Halozyme Therapeutics scores higher on the StockData Score (13 against 5 for Moderna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HALO | MRNA |
|---|---|---|
| Size and price | ||
| Market cap | $14.9B | $88.5B |
| Share price | $130.91 | $221.72 |
| Change, 1 year | 101% | 798% |
| Change, 5 years | 222% | −6.4% |
| Beta (5Y) | 0.71 | 1.11 |
| Employees | 423 | 4,700 |
| StockData Score | ||
| Total score | 13 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 5 (better) | 1 |
| Health score | 4 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 38.6× | – |
| P/S | 8.9× (better) | 39.7× |
| P/B | 104× | 13.1× (better) |
| EV/EBITDA | 27.5× | – |
| P/FCF | 18.4× | – |
| PEG | 1.83 | – |
| FCF yield | 5.4% (better) | −1.4% |
| Fair value | $69.98 | $33.24 |
| Margin of safety | −87.1% (better) | −567% |
| Growth | ||
| Revenue growth (TTM) | 41.2% (better) | −27.6% |
| Revenue growth, 5Y average | 39.2% (better) | 19.3% |
| Net income growth (TTM) | −25.8% | – |
| EPS growth (TTM) | −22.4% | – |
| EPS growth, 5Y average | 23.0% | – |
| Profitability | ||
| Gross margin | 82.4% (better) | 23.4% |
| Operating margin | 35.9% (better) | −149% |
| Net margin | 24.9% (better) | −141% |
| FCF margin | 48.5% (better) | −55.8% |
| Return on equity | 174% (better) | −39.0% |
| Return on invested capital | 21.7% (better) | −80.9% |
| Financial health | ||
| Debt / equity | 14.95 | 0.09 (better) |
| Net debt / EBITDA | 3.24 | – |
| Interest coverage | 29.4× | – |
| Current ratio | 2.71 (better) | 2.29 |
| Altman Z-score | 5.43 | 12.86 (better) |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 109% | 79.9% |
| Held by insiders | 1.3% | 5.6% |
| Insider net buying, 12 months | −$41.2M (better) | −$64.6M |
| Short interest, % of float | 13.7% | 8.2% |
Go deeper
- HALO stock overview
- HALO income statement
- HALO valuation and score
- MRNA stock overview
- MRNA income statement
- MRNA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.